Ava Advisor

npx add-mcp 'https://mcp.ava.fund/mcp'

Live News

The market this week

▼2 ▲1

AI spending doubts hit Big Tech, but chip and AI orders stay strong

• Investors balk at Big Tech's AI bills Alphabet, Amazon and Meta all spent more cash than they took in as they build AI data centers, and their combined planned spending tops $740 billion this year. Alphabet had its worst day ever, down about 12%, and S&P cut Meta's credit outlook. The Nasdaq 100 fell 6.7% in October, its worst month since March 2025. This is the main force pulling US stocks down this period: the market is questioning whether huge AI spending pays off.
• AI fundraising gets harder OpenAI cut its fundraising target to $20 billion from $30 billion and its expected value to $1.25 trillion, as investors push back on AI spending. Blackstone warned Anthropic may not earn an investment-grade credit rating after its IPO. Money for AI is getting tighter and more expensive, a drag on the whole buildout. Shows the financing side of AI cooling, which affects how the buildout gets paid for.
• Chip and AI demand still booming AMD's data-center sales jumped 97% to a record, with a strong outlook and a deal to supply Anthropic with up to 2 gigawatts of chips. Super Micro's revenue nearly quadrupled and it raised guidance. Palantir's revenue rose 96% on US commercial sales up 148%. Microsoft's Azure cloud grew 48%. Demand is real even as spending worries bite. The counterweight: actual orders and profits keep rising, so the AI boom is not just spending without customers.
• Oil near $118 lifts energy, squeezes the rest Brent crude is heading for a 13-14% monthly gain near $118 a barrel as US-Iran tensions threaten the Strait of Hormuz. Exxon and Chevron beat profit estimates, but high fuel costs feed inflation and keep the Fed cautious, a headwind for consumers, airlines and expensive stocks. Energy is a major sector force: it boosts oil producers while raising costs and inflation risk for the wider market.

Based on 22 stories →

▼2

AI debt fears, hot inflation and war-driven oil keep rates high

• AI's debt-funded buildout hits a wall Big Tech's AI spending is now so large it has turned cash flow negative: combined quarterly capex hit a record $201.9 billion and combined free cash flow went negative $26.4 billion. Alphabet had its worst day ever, Meta's outlook was cut to negative, and Oracle is raising $20 billion. Investors fear the borrowing, not the chips, is now the limit — pressuring Nvidia, Broadcom, Oracle and the hyperscalers. This is the period's dominant force: AI capex turning cash-flow negative and debt-funded, hitting tech and chip stocks.
• Inflation stays hot, central banks turn hawkish again US inflation held at 3.6% (core 3.1%), with energy prices up over 21% on the oil war. The Fed is expected to hike in December, and the ECB, Bank of Japan and Bank of England all signaled or delivered hikes. Higher-for-longer rates raise borrowing costs for everyone and weigh on banks, homebuilders and expensive tech stocks. Answers the rates/inflation part of the question directly: hot inflation plus a global hawkish turn.
• Oil near $115 on Iran war, but diplomacy caps the spike Brent held around $111–118 as Hormuz attacks and US-Iran tensions kept a war premium, then slipped as Trump favored diplomacy before the midterms. Energy producers and refiners are the big winners — Shell profit doubled on record refining margins, Exxon and Chevron beat — while airlines, truckers and consumers pay record fuel costs that feed inflation. Oil is the main driver of the inflation and geopolitics behind the rate story, with clear winners and losers.
• Growth splits: chips boom in Korea, metals gain, US midterms add uncertainty South Korea's exports jumped 93.7%, fastest since 1974, on AI chip demand, lifting Samsung and SK Hynix to record profits. Higher metal prices and tariffs boosted Freeport, Nucor and ATI. But a Democratic sweep of Congress raised fears of stricter AI and crypto rules, hitting chip stocks and Bitcoin. Shows the growth side of the question and the real counterweight — a chip boom — against the AI-spending gloom.

Based on 24 stories →

▲2 ▼1

Memory boom spreads, oil war risk persists, Europe gas spikes

• Memory chip boom broadens beyond the giants Chinese memory makers posted huge profit jumps: ChangXin swung to a 132bn yuan profit and plans a buyback, Puya's profit rose 3,875% and CECport's 360%. South Korea's chip exports rose 259%, the fastest export growth since 1974. This lifts memory makers like SK Hynix and Samsung, but squeezes device makers. It is the period's clearest new evidence that the AI memory shortage is still widening and spreading to Chinese suppliers.
• Memory costs now bite the buyers Apple fell 4% as its new CEO said memory prices are rising at an unprecedented pace and will climb further. Intel sank 29% on weak guidance, blaming a memory crunch and substrate shortage. Sandisk beat but fell 13% on fears high memory prices will shrink device sales. Makers gain; device makers lose. It shows the boom's other side: the cost squeeze is now hitting real earnings at Apple and Intel.
• Oil and refining profits stay at record highs Brent ended October near $118, up 13.6% on the month, as Hormuz attacks hit a monthly record and four tankers were reported destroyed by mines. Exxon earned $15.4bn, Chevron $9.9bn, BP $4.7bn and Marathon $26.93 a share at 100% refinery use. Producers and refiners gain; fuel buyers pay. It confirms war-driven oil and record refining margins are still the market's biggest profit engine.
• High fuel costs hit airlines and gas users Ryanair's fuel bill will jump about €2bn as unhedged jet fuel doubled to ~$130 a barrel, and first-half profit fell 15%. European gas hit €100/MWh, a four-year high, with storage at 75% versus 83% last year and LNG imports down 30%. Airlines and energy consumers lose; gas suppliers gain. It is the clearest new sign that energy costs are now hurting transport and European consumers, not just boosting producers.

Based on 24 stories →

▲2 ▼1

Rare disease sales beat expectations; one trial fails as kidney-drug race tightens

• Approved rare disease drugs post strong, growing sales Biogen, Alnylam, BridgeBio, PTC, AstraZeneca and Regeneron all beat or raised on rare disease sales: Skyclarys up 34%, Amvuttra-led TTR sales up 59%, Attruby at $253 million, Sephience past 2,000 patients, Ultomiris up 19%. Real revenue growth shows demand for approved rare medicines is durable and funds the next wave of research. Six of the period's stories show rare disease revenue beating expectations, the clearest force lifting the theme.
• Pipeline and launch calendar keep expanding Vertex's povetacicept met all Phase 3 goals in IgA nephropathy and will seek accelerated FDA approval. BridgeBio has three priority-review approval decisions in seven months, Alnylam is enlarging its ATTR-CM trial, and Regeneron won FDA approval for Pasatru in FOP. Each adds a future market. New trial wins and near-term approval dates are the main additions to the theme's future supply of treatments.
• A late-stage failure shows clinical risk is still real Geron stopped its Phase 3 myelofibrosis trial after an independent committee said it was unlikely to meet its survival goal, and shares fell 12%. It is a reminder that even late-stage rare disease bets can fail outright, which keeps investors cautious on single-drug companies. This is the period's main counterweight, showing the high clinical risk that can sink individual rare disease names.
• Kidney-disease race gets more crowded Vertex's positive povetacicept results add a third strong IgA nephropathy option alongside AstraZeneca's newly approved Ultomiris and Roche/Ionis's sefaxersen. More patients can be treated, but several competing drugs in one rare disease usually means tougher pricing and share fights for each. It extends the kidney-disease competition story with a new entrant, changing the balance of winners and losers.

Based on 8 stories →

▲2 ▼1

Vertical software demand holds up, but growth is uneven and AI splits winners from losers

• Industry-specific software keeps winning customers Software built for one industry's core work is still selling well. Dassault Systèmes raised its full-year outlook for the first time in two years, helped by its life-sciences purchase, and Intapp's subscription revenue rose 29% with its new AI product already over 40% of new bookings. Asure, Jack Henry and Blackbaud also grew steadily. Shows the theme's core demand engine is still intact across several verticals.
• Some verticals hit booking and guidance shortfalls Not everyone is growing smoothly. CoStar fell 13% as new bookings came in at just $37 million, blamed on sales staffing and economic headwinds. SS&C guided fourth-quarter revenue below expectations, Tyler missed on revenue with soft profit guidance, and ATOSS cut its full-year outlook to the low end. The real counterweight: growth is cooling for several names, so the theme is not uniformly strong.
• Cash-rich vertical software buys AI and adjacent markets Profitable vertical software firms are using cash to buy growth. Guidewire is buying AI underwriting firm hyperexponential and launched an AI-driven insurance platform, Amdocs paid about $340 million for insurance software maker EIS, and Asure bought a payroll company. Guidewire also bought back $606 million of stock. Shows capital being deployed into AI and new verticals, a force shaping the theme's future growth.
• AI demand is real but regulation and disputes add risk AI is lifting some names: Palantir's revenue growth accelerated to 96%, and Veeva and EverQuote point to AI-driven products. But Toast is fighting an FTC lawsuit over recurring fees in business contracts, and Amdocs warned a contract dispute with T-Mobile will cut fiscal 2027 revenue sharply. Captures both the AI upside and the legal and customer-concentration risks now hitting vertical software.

Based on 24 stories →

▲3 ▼1

AI power deals and grid spending surge; Europe's gas crunch deepens

• Data-center power demand turns into hard orders Generac's data-center backlog nearly tripled to about $4.5bn in 90 days, with an Amazon deal worth $2.4bn of generator deliveries in 2027-28. Eaton's data-center orders more than doubled and its electrical backlog passed $20bn. FirstEnergy sees 7.9 GW of contracted data-center load and will lift its $19bn transmission plan by at least 25%. Shows the theme's core demand force converting into signed, multi-year orders across generators, electrical gear and wires.
• Grid and storage builders spend big to keep up GE Vernova is paying $9bn for Trench Group to bring high-voltage grid equipment in-house, and Quanta posted record results with backlog near $64bn, up $10bn in a quarter, while doubling transformer capacity. In China, a consortium signed a 3.64bn yuan (about $500m) 1 GW/4 GWh battery storage contract. Capital flowing into grid hardware and storage capacity is what lets the power buildout actually happen.
• Nuclear and fuel cells win long-term backing Constellation locked a 20-year Google deal for 890 MW of reactor upgrades worth over $4.3bn, plus a conditional $5bn DOE loan for up to 1.1 GW of uprates. Bloom Energy jumped on a Barclays upgrade and a California plan for at least 1 GW of fuel cells with carbon capture; customer deposits imply roughly $3bn of contracts. Long contracts and federal loans lock in years of steady, round-the-clock power demand.
• Europe's gas squeeze raises power costs European gas hit 100 euros per MWh, a four-year high, as storage sits at 75% versus 83% last year and Germany's falls to a record-low 61%, with analysts warning of a possible 20-25% finish to winter. Costlier fuel raises bills and project costs, a real drag even as demand grows. The main counterweight: expensive, scarce fuel raises the cost of the power the buildout needs.

Based on 24 stories →

▲2 ▼1

Senior housing capital surges while device demand cools and drugmakers defy pricing pressure

• Senior housing draws big money and takeover interest Welltower raised its 2026 guidance after property income from its senior housing jumped 21%, and it has committed $21 billion to new investments. In Australia, a A$2.2 billion takeover bid for retirement-community operator Ingenia set off a bidding contest. Both show investors paying up for buildings that house a growing elderly population. Shows capital and demand strength in the senior housing sub-area, a core Aging Population exposure.
• Drugmakers post record sales and shrug off price pressure Lilly's revenue rose 39% to $24.4 billion on Mounjaro and Zepbound, and it raised guidance. Merck, Bristol Myers and AbbVie also beat estimates and lifted forecasts, with AbbVie's Parkinson's drug Juvmo approved. Companies say rising volumes will outweigh Trump's push to cut U.S. drug prices. Confirms aging-driven chronic-disease drug demand is strong and resilient to pricing policy.
• Hip, knee and heart-device sales slow as patients balk at costs Stryker cut its 2026 sales outlook, citing slower U.S. hip and knee procedures as higher insurance premiums and deductibles, plus more pre-authorization denials, put patients off. Boston Scientific fell 6% on weak heart devices and flagged more weakness into 2027. Demand for age-related devices is softer than expected. A real counterweight: the devices side of the theme is slowing even as drug and housing demand stays strong.

Based on 8 stories →

▼2 ▲1

Lp(a) class stumbles, Alnylam cools, but heart-drug sales keep climbing

• A big cholesterol-gene drug fails, casting doubt on a whole class Novartis and Ionis's pelacarsen lowered Lp(a) but did not cut heart attacks or strokes in an 8,000-patient Phase 3 trial. That removes a hoped-for growth driver and raises the proof bar for Amgen's olpasiran and Eli Lilly's lepodisiran, which face the same binary risk. It is the period's biggest negative force on cardiovascular drug expectations and hits several companies at once.
• Alnylam's ATTR heart franchise cools on demand and trial-design worries Alnylam fell 25% as Amvuttra sales missed estimates and patient starts lagged, with 340B and Medicare Advantage headwinds ahead; Bernstein then downgraded it, cutting success odds for the next-generation ATTR drug nucresiran. This is a real counterweight to the fast-growing ATTR market. It shows the strongest ATTR player hitting demand and pipeline doubts, tempering the theme's best growth story.
• Heart-muscle drug sales ramp fast as approvals convert to revenue Cytokinetics' HCM pill Micorzo reached $44.5 million in quarterly sales, up 76% in three months, with about 2,800 patients dispensed, and new late-stage aficamten data landed. Mineralys is weeks from a December 22 FDA decision on its blood-pressure drug with $625 million to fund launch. It shows approved heart drugs turning into real, rapidly growing revenue rather than just pipeline promise.
• Pipeline bets advance but late-stage risk keeps biting Roivant's pulmonary-hypertension drug cut vascular resistance 56% in Phase 2, a strong signal, while AstraZeneca's 2027 heart and kidney readouts underpin its growth case. Against that, Tenax paused enrollment in its follow-up heart-failure trial to target sicker patients after its first late-stage miss. It captures both the promising new heart pipeline and the reminder that late-stage heart trials can still fail.

Based on 13 stories →

▲2 ▼1

Tokenized rails deepen in funds and bonds, but issuers keep blocking stock tokens

• Company objections to OKX-ICE tokenized stocks keep snowballing The list of US-listed companies formally objecting to their shares trading as tokens on the OKX-ICE venue grew from 16 to 38, now including JPMorgan, IBM, Intel, Coca-Cola, Adobe, Walmart and Eli Lilly. Under the SEC exemption, companies can opt out — so the flagship third-party tokenized-stock venue risks having little left to list. This is the biggest new force this period and a direct brake on tokenizing existing US shares.
• Big asset managers put real money into tokenized funds Aviva Investors launched a tokenized share class of its £22bn sterling money fund on the XRP Ledger, committing £50m. BlackRock and SBI agreed to study linking tokenized money market funds to Japan's yen stablecoin. Tokenized funds are moving from pilots to funded products with named managers behind them. Shows established asset managers committing actual capital to tokenized fund rails, not just testing.
• Settlement and issuance rails widen: DTCC, ESM, Mirae, Japan real estate DTCC opened tokenized trading of 34 Russell 1000 stocks, ETFs and Treasuries worth about $30tn with 20 banks signed up. Europe's ESM issued a €1bn digital bond settled in central bank money, Mirae sold tokenized notes on Solana, and Daiwa plans about ¥30bn of real-estate digital securities for individuals. Shows the plumbing and issuance side of tokenized securities broadening across regions and asset types.
• Regulated on-ramps grow in Japan and Thailand, but retail crypto demand cools Ripple won a US national bank charter, SMBC Nikko is building a regulated DeFi platform aimed at tokenized equities, and Thailand's SEC sent an electronic-securities law to parliament. But Robinhood's crypto revenue fell 55% year on year, a reminder that retail trading demand is uneven even as rails improve. Balances the infrastructure progress with a real signal that end-user crypto demand is not steadily rising.

Based on 16 stories →

▲2 ▼1

Fortinet's service-revenue cut cools security stocks despite strong sales

• Fortinet's service revenue miss drags the whole security group down Fortinet beat quarterly sales and profit and raised its 2026 outlook for the third time, yet cut its full-year service revenue forecast, implying weaker add-on sales of bundled networking and secure-access products on its firewalls. The stock fell 25% and pulled CrowdStrike, Palo Alto, Okta and Zscaler down over 5% each. This is the period's dominant event: a demand signal from the firewall leader that hit the whole theme.
• Fortinet's core hardware and billings still growing fast Underneath the guidance cut, Fortinet's product revenue jumped 37% and billings rose 29%, with price increases adding about 10 points. Record 38% operating margin and a bigger buyback show firewall demand tied to AI security is still strong, even if add-on subscriptions lag. It is the real counterweight: the underlying demand for network security hardware remains healthy.
• AI-assisted attacks on real victims widen the market for defense Breaches at Sagawa Express, Capcom and Burger King, AI-driven attack tools, tampered refrigeration at French supermarkets and attacks on US water utilities show attackers moving faster than defenders. Japan's incidents already beat last year's total, pushing companies and governments to spend more on monitoring and response. Real attacks are the demand engine for endpoint and network security spending.
• Japan's active cyber defense law gets its first big test After attacks on its forex service, GMO Internet asked Tokyo to use its new active cyber defense law, which lets police and the military strike back at attackers' servers. The government is weighing it; GMO shares fell 15%. State-backed defense could add public spending, but the rules are untested. A new regulatory lever that could expand government-funded network defense, with unclear near-term effect.

Based on 5 stories →